What is the interpretation of the lumbar spine and femoral neck bone mineral density results and the recommended treatment for a 65‑year‑old woman with lumbar spine osteoporosis (T‑score –2.7) and femoral‑neck osteopenia (T‑score –1.7) according to WHO classification and the National Osteoporosis Foundation guidelines?

Interpretation and Treatment Recommendation for 65-Year-Old Woman with Lumbar Spine Osteoporosis

This 65-year-old woman requires pharmacologic treatment for osteoporosis based on her lumbar spine T-score of -2.7, and first-line therapy should be an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly), denosumab 60 mg subcutaneously every 6 months, or zoledronic acid 5 mg IV annually. 1

Bone Density Results Interpretation

Diagnosis: This patient has osteoporosis by WHO criteria based on the lumbar spine T-score of -2.5 or lower, despite having only osteopenia at the femoral neck. 1

Site-Specific Findings:

• Lumbar spine: T-score -2.7 (osteoporosis), Z-score -1.0 1
• Left femoral neck: T-score -1.7 (osteopenia), Z-score -0.2 1

Important caveat: In 65-year-old women, degenerative changes in the lumbar spine (osteophytes, facet joint arthritis, aortic calcification) can artificially elevate BMD measurements. 2, 3 However, in this case, the lumbar spine T-score is lower than the hip, making degenerative artifact unlikely and confirming true osteoporosis. 2

FRAX Assessment Requirement

Before finalizing treatment decisions, calculate the 10-year fracture probability using FRAX. 1 While this patient already meets treatment criteria based on T-score alone (≤-2.5), FRAX calculation helps determine if she is at "very high risk" versus "high risk," which influences treatment selection and duration. 1

Treatment Thresholds (Already Met):

• T-score ≤-2.5 at any site = automatic treatment indication 1
• Alternative threshold: T-score between -1.0 and -2.5 with FRAX ≥20% for major osteoporotic fracture OR ≥3% for hip fracture 1

Risk Stratification

High Risk Features (assess for these):

• T-score ≤-2.5 (present in this patient) 1
• FRAX major osteoporotic fracture 20-30% or hip fracture 3-4.5% 1

Very High Risk Features (assess for these):

• Recent fracture within past 12 months 1
• Multiple fractures 1
• T-score <-3.0 1
• FRAX major osteoporotic fracture >30% or hip fracture >4.5% 1
• Fracture while on osteoporosis therapy 1

If this patient has any very high risk features, anabolic therapy (teriparatide, abaloparatide, or romosozumab) should be considered as initial treatment instead of antiresorptive therapy. 1

First-Line Pharmacologic Treatment Options

For High Risk (No Very High Risk Features):

Preferred agents with proven hip, vertebral, and nonvertebral fracture reduction: 1

• Alendronate 70 mg orally weekly 1
• Risedronate 35 mg orally weekly 1
• Zoledronic acid 5 mg IV annually 1
• Denosumab 60 mg subcutaneously every 6 months 1

For Very High Risk (If Applicable):

Anabolic agents should be considered first: 1

• Teriparatide 20 mcg subcutaneously daily (limit to 2 years) 1
• Abaloparatide 80 mcg subcutaneously daily (limit to 2 years) 1
• Romosozumab 210 mg subcutaneously monthly (limit to 1 year) 1
• Zoledronic acid 5 mg IV annually 1

Critical: After completing anabolic therapy, transition immediately to bisphosphonate or denosumab to maintain gains and prevent rapid bone loss. 1

Essential Non-Pharmacologic Interventions

All patients require these foundational measures: 4, 1

Calcium and Vitamin D:

• Calcium 1,000-1,200 mg daily (dietary plus supplement) 4, 1
• Vitamin D 800-1,000 IU daily (target 25-OH vitamin D >30 ng/mL) 4, 1

Lifestyle Modifications:

• Weight-bearing exercise 30-40 minutes, 3-4 days per week (walking, resistance training) 1, 5
• Balance exercises to reduce fall risk 1, 5
• Smoking cessation (if applicable) 1, 5
• Limit alcohol to ≤2 drinks daily 5

Fall Prevention:

• Home safety assessment (remove tripping hazards, improve lighting, install grab bars) 1, 5
• Vision and hearing assessment 5
• Medication review (minimize sedating medications) 5
• Consider physical therapy referral for gait training and strengthening 1, 5

Monitoring and Follow-Up

Baseline Evaluation Before Treatment:

• Serum calcium, phosphorus, creatinine, 25-OH vitamin D 6
• Consider secondary causes workup if Z-score ≤-2.0 or other risk factors present 6

DXA Monitoring:

• Repeat DXA in 1-2 years after starting treatment, then every 1-2 years until stable 1
• Monitor lumbar spine and total hip (same machine/facility when possible) 1

Bone Turnover Markers (Optional):

• Baseline and 3-6 months after starting antiresorptive therapy to assess compliance and response 1
• Target: reduction to premenopausal median range 1

Treatment Duration

Oral Bisphosphonates:

• Treat for 5 years, then reassess for drug holiday if fracture risk no longer high (T-score >-2.5, no fractures) 1
• Continue beyond 5 years if T-score ≤-2.5 or prior fracture 1

IV Zoledronic Acid:

• Treat for 3 years, then reassess for drug holiday 1

Denosumab:

• No defined treatment duration limit 1
• Critical: Do NOT abruptly discontinue due to rebound bone loss and vertebral fracture risk 7
• If stopping denosumab, transition to bisphosphonate 7, 1

Common Pitfalls to Avoid

1. Do not rely solely on femoral neck T-score when lumbar spine shows osteoporosis—treat based on the lowest T-score at any site 1, 8

2. Do not use single vertebra T-scores (L1, L2, L3, or L4 alone) for diagnosis—use L1-L4 total 8

3. Do not delay treatment while waiting for FRAX calculation when T-score already ≤-2.5 4, 1

4. Do not forget to evaluate for secondary causes of osteoporosis, especially with Z-score ≤-2.0 6

5. Do not discontinue denosumab without transition therapy—this causes rapid bone loss and increased vertebral fracture risk 7, 1